Jun. 22 at 10:28 AM
$OSTX This may be the most important week of 2026 for OS Therapies.
🔹 BIO International Convention (6/22)– The world’s largest biotech partnering event. Management is meeting with potential partners, licensors, and strategic collaborators. Any partnership, licensing, or co-development deal could emerge from these discussions.
🔹 MIB Conference (6/25)- Detailed 2.5 year survival data revealed. Opportunities to increase institutional awareness, attract new investors, and advance strategic relationships.
Potential news still ahead:
✅ OST-504 Phase 1b prostate cancer data, guided for release by the end of June.
✅ FDA pre-BLA meeting outcome for OST-HER2, which could provide further clarity on the Accelerated Approval pathway and BLA submission.
✅ Partnership or licensing announcements.
✅ Additional regulatory updates as OSTX advances filings globally.
It’s extremely rare for a micro-cap biotech company to have this many potential value-driving events stacked so closely together.
